Table 1 Demographic and clinical-pathological characteristics of the patients
SLN = 1 n. 328 | SLN >1 n. 752 | P-value | |||
|---|---|---|---|---|---|
n. | % | n. | % | ||
Age (years) | |||||
<40 | 12 | 3.6% | 20 | 2.7% | 0.91 |
40–49 | 56 | 17% | 112 | 15% | |
50–69 | 216 | 66% | 524 | 69.6% | |
>70 | 44 | 13.4% | 96 | 12.7% | |
Tumor size | |||||
T1(<20mm) | 216 | 65.8% | 536 | 71% | 0.45 |
T2 or greater | 112 | 32.9% | 216 | 29% | |
Grading | |||||
I | 96 | 29.3% | 196 | 26% | 0.95 |
II | 156 | 47.6% | 384 | 51% | |
III | 52 | 15.8% | 116 | 15.5% | |
Indeterminate | 24 | 7.3% | 56 | 7.5% | |
Histology | |||||
Invasive ductal | 240 | 73.2% | 568 | 75.5% | 0.91 |
Invasive lobular | 36 | 10.9% | 72 | 9.6% | |
Others | 52 | 15.9% | 112 | 14.9% | |
Receptor status | |||||
ER+ | 294 | 89.6% | 660 | 87.7% | 0.79 |
PR+ | 270 | 82.2% | 605 | 80.5% | |
HER2/neu+ | 107 | 32.7% | 240 | 31.9% | |
ER+, PR+, HER2+ | 75 | 22.8% | 168 | 22.4% | |
Triple negative | 13 | 4.1% | 49 | 6.5% | |